Present study reports changes in serum copper levels (SCL) in various neoplastic diseases undergoing radiotherapy. We estimated SCLs in 140 individuals comprising of 90 previously untreated patients with various malignancies and 50 healthy controls. Patients received radiation in doses of 40-70 Gy in 4-7 weeks. SCLs were again estimated in patients following irradiation, the mean SCL was significantly higher (P<0.001) in cancer patients as compared to healthy controls. It declined significantly (P<0.001) following irradiation. However, it remained significantly higher as compared to healthy controls (P<0.01). Highest fall in SCL was seen in complete clinical responders and least in non-responders to radiation treatment. Serial estimation of SCLs may be useful in the treatment monitoring of the neoplasms undergoing radiation treatment.
INRODUCTION
Cancer is known to be the second most common cause of death after heart disease worldover. Radiation has been used for a century to treat various malignant disorders as a single modality or in combination with surgery and/or chemotherapy. In majority of the neoplastic diseases, we lack exact biochemical parameters to monitor the radiation therapy and its outcome.
It is well established that the element copper is biologically essential for normal growth and development of human body and its function. Very little is known about the clinical significance of serum copper level (SCL) in various disease states including malignancy. Several investigations (1-8) studied serum copper in various malignant disorders. They consistently found it to be elevated in such patients except in few urogenital malignancies (1) .
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Tessmer et.al. (2) studied the usefulness of SCLs in malignant diseases to assess the response to radiation treatment. Hrgovcic et.al, (3) and Thorling and Thorling (9) found the clinical usefulness of SCLs in Hodgkins disease to assess the response to therapy. And, Sharma et.al., (10) found a role for SCL in treatment monitoring of breast cancer.
Recently Martin-Lagos et.al. (5) did not find significant elevation in mean SCLs in cancer patients as compared to controls. Jacobs et.al. (11) failed to find a useful role for SCLs in the treatment monitoring of epithelial ovarian malignancy. Jayadeep et.al (7) did not find any significant role for SCL as a biomarker of disease progression in the squamous cell carcinoma of oral cavity.
It is clear from above that the interest on the role of trace elements in malignancies is revived, but there is no unanimity regarding their use in monotoring disease. In view of these controversial reports, the present study investigates the role for serum copper ~n the treatment monitoring of patients with various malignancies undergoing radiotherapy.
MATERIALS AND METHODS

Patients
The present study is based on the estimation of SCLs in 140 individuals included in the study and control group. Study group comprised of 90 previously untreated, histologically proven patients with various malignancies otherwise free from any concurrent illness. All patients underwent routine haematoiogical and biochemical work up of liver and kidney functions, a chest X-ray PA view and other investigations including Barium swallow, ultrasonography of abdomen, CT scan and endoscopies as indicated. All patients were clinically staged. They gave an informed consent to participate in this study.
Methods
SCLs were estimated both pre and postirradiation in all the patients by Atomic Absorption Spectrometry method(12) from the venous blood samples. We also estimated SCLs in the blood samples from the healthy voluntary blood donors in our hospital who served as controls.
Interventions
All the patients underwent radiation treatment with the help of telecobalt (Theratron 780-C, AECL, Ottawa). A dose of 40-70 Gy in fraction sizes of 2 Gy was delivered 5 days in a week over a period of 4-7 weeks. Spinal cord was spared after a dose of 40 Gy where required.
Response assessment
Responses were assessed for the disease one month following the completion of radiotherapy and were categorized as a complete response (CR) i.e. complete disappearance of all tumours on clinical examination, partial response (PR) i.e. greater than 50% reduction in the tumour size, or no response (NR) i.e. less than 50% reduction, stable disease or progression.
Statistical methods
For difference between means of measured values of SCLs in various groups or pre-and posttherapy, the student's test was used.
RESULTS
A total of 90 patients were in the study group. The characteristics of these patients are shown in Table 1 . Fifty healthy blood donors served as the controls.
The mean pre-treatment SCL was significantly higher (P<O.01) in the subjects (total) with the malignancy (182+24.2 pg %) as compared to the control (107+13.3 t~g%) ( Table 2 ). There was no statistically significant difference between the mean SCLs of the various age groups or sexes, either in controls or subjects with malignancy.
SCLs were analysed between the various types of malignancies being studied. Nearly similar mean serum copper values were observed in the patients suffering from various cancers. An effort was made to see the variations in SCLs in different clinical stages (stage I-IV) of the disease; and early (stages I &ll) versus late disease (stages III & IV). No significant differences were observed in various such subsets of the patients.
Following radiotherapy, there was a decline in SCLs in 82% patients (74/90), while there was an elevation in serum levels in remaining 18% of The total mean post-therapy SCL came down to 136 + 27.91~g % from the mean pre-treatment level of 182+24.2~g %. This decline in the mean of 46+19.61~g% (not shown in table 3) was statistically highly significant (P<0.01). However, the mean post-treatment level was significantly higher than the mean SCL of healthy controls (P<0.01).
An effort was made to see the correlation between the clinical response and changes in serum copper levels following the radiotherapy (Table 3 ). It was observed that the decline in mean SCL was highest in patients achieving CR versus those with PR or NR. There was a statistically significant difference between the decline in the mean in patients with CR and PR (P<0.01) and also between PR and NR (P<0.05). There was no significant difference between the mean posttherapy SCLs in patients with complete clinical response (110+17.21~g%) and mean levels in healthy controls. However, mean post-therapy level in patients with PR was 146+24.2#g%, which was significantly higher than the mean SCL in controls (P<0.01).
The decline in mean SCLs was compared between early stages (stage I & II) and late stages (stage III & IV) of the disease. There was a significantly higher fall in mean SCL of patients with early disease (54+25.6#g%) as compared to late stages (41+21.4#g%) (P<0.05 not shown in table). An effort was also made to see the differences in mean decline in SCLs with various doses of radiation. But no correlatior was observed.
DISCUSSION
A total of 90 subjects with various malignancies were included in the present study. The mean SCLs were significantly higher in pateitns with various cancers as compared to healthy controls (P<0.001). Many researchers (1-8) found significant elevation in SCLs in various malignancies except in patients with prostatic carcinoma and few renal neoplasms (6) .
No significant differences were observed in the SCLs in the various clinical stages of the disease in the present study. However, Margalioth et.al. (13) studied SCLs in various gynaecologic malignancies and found that SCLs correlated well with the stage of the cancer except in cases with ovarian neoplasm. Thorling and Thorling(9) found statistically significant correlation between the stage of the Hodgkins disease and SCL. However, we did not find any such correlation. Sanada et.al. (6) also did not find a distinct relationship between SCLs and extent of the disease in transitional cell carcinoma of the bladder.
Hrgovcic et.al. (3) and Thorling and Thorling, (9) in their studies of Hodgkins disease found that serum copper is regularly reduced to within normal limits at complete remission and they proposed that thrs parameter be included in the criteria for complete remission. Sood et.al.(4) studied prospectively changes in SCLs in patients with various malignancies including carcinomas, sarcomas and lymphomas treated with surgery, radiotherapy or chemotherapy. They concluded that SCL is a potentially valuable biochemical index for assessing the efficacy of therapy and as a guide to prognosis. Sanada et.al. (6) evaluated the changes in SCLs in patients with malignant neoplasms of the urogenital tract. They found that SCLs decreased in testicutar cancer patients responding to therapy and increased again tn relapse. In a study of SCLS in breast malignancy, Sharma et.al (10) postulated that the levels of this trace element may help in diagnosis and prognosis of disease. However, Jacobs et.al. (11) in their study of SCLs in ovarian malignancy concluded that serum copper determination has no use in the treatment monitoring of epithelial ovarian carcinoma. Jayadeep et.al. 1997(7) in their study of SCLs in 92 patients of squamous cell carcinoma of oral cavity concluded that serum copper determination has a little value as biomarker of disease progression.
In the present study, the greatest decline in mean SCL was observed in patients with complete clinical response while least decline of mean was found in patients with no response to radiotherapy ( Table 3 ). The mean post-therapy SCL in patients with CR was near normal, whereas it remained significantly elevated in patients with PR or NR (p<O.001) as compared to controls. And significantly higher decline in mean SCL was observed in patients with early malignancy (stages-I & II) as compared to patients with advanced disease (stages III & I~/).
From the results of the present study, it may be concluded that decline in SCLs are strongly related to the response to radiotherapy. Measurement of serum copper levels during radiotherapy may be helpful in treatment monitoring of such cancers. However, this study needs to be conducted on a larger patient population to assess a clinical role for this biomolecule in the treatment monitoring of various neoplasms undergoing radiation treatment.
